Who Paid My Doc
A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3)
ClinicalTrials.gov NCT02975934
Research payments
$5,612,343
Through program year 2022, $5,612,343 in research payments was reported against A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3), across 917 payments, paid by Clovis Oncology, Inc..
- Paid by
- Clovis Oncology, Inc.
- ClinicalTrials.gov
- NCT02975934
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2022 | Research | $805,179 | 119 |
| 2021 | Research | $1,194,021 | 249 |
| 2020 | Research | $2,006,188 | 313 |
| 2019 | Research | $1,606,955 | 236 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Young Whang Chapel Hill, NC Named on 53 payments
- Daniel Petrylak New Haven, CT Named on 50 payments
- Charles Redfern San Diego, CA Named on 47 payments
- Alan Bryce Scottsdale, AZ Named on 43 payments
- Julie Graff Portland, OR Named on 27 payments
- Julio Hajdenberg Orlando, FL Named on 26 payments
- Wassim Abida New York, NY Named on 24 payments
- Wes Lee Santa Rosa, CA Named on 21 payments
- Shih-Hsin Yang Birmingham, AL Named on 20 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.